Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Registrative trials recommended the use of upfront chemotherapy in high-volume metastatic prostate cancer. We reported survival outcomes of patients with high-volume mCRPC treated with ARTA in a chemo-naïve setting compared to patients treated with chemotherapy as first-line from a longitudinal real-life multicenter series. We retrospectively collected data on mCRPC patients treated at six centers. The dataset was queried for high-volume disease (defined as more than 6 bone lesions or bulky nodes ≥ 5 cm). We compared the main clinical features of chemo-naïve versus chemo-treated patients. The Mann–Whitney U test and Chi-squared test were used to compare continuous and categorial variables, respectively. The Kaplan–Meier method was used to compare differences in terms of progression-free survival (PFS), cancer specific survival (CSS) and overall survival (OS) in an upfront ARTA or chemo-treated setting. Survival probabilities were computed at 12, 24, 48, and 60 months. Out of 216 patients, 88 cases with high-volume disease were selected. Sixty-nine patients (78.4%) received upfront ARTA, while 19 patients received chemotherapy as the first-line treatment option. Forty-eight patients received Abiraterone (AA), 21 patients received Enzalutamide (EZ) as the first-line treatment. The ARTA population was older (p = 0.007) and less likely to receive further lines of treatment (p = 0.001) than the chemo-treated cohort. The five-year PFS, CSS and OS were 60%, 73.3%, and 72.9%, respectively. Overall, 28 patients (31.8%) shifted after their first-line therapy to a second-line therapy: EZ was prescribed in 17 cases, AA in seven cases and radiometabolic therapy in four patients. Sixteen cases (18.2%) developed significant progression and were treated with chemotherapy. At Kaplan–Meyer analysis PFS, CSS and OS were comparable for upfront ARTA vs chemo-treated patients (log rank p = 0.10, p = 0.64 and p = 0.36, respectively). We reported comparable survival probabilities in a real-life series of high-volume mCRPC patients who either received upfront ARTA or chemotherapy. Patients primarily treated with chemotherapy were younger and more likely to receive further treatment lines than the upfront ARTA cohort. Our data support the use of novel antiandrogens as first line treatment regardless tumor burden, delaying the beginning of a more toxic chemotherapy in case of significant disease progression.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort
- Date Crossref
- 29/09/2023
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
Campus Bio Medico University Hospital pays non établi dans la noticeÉtablissement de santé
-
Carlo Forlanini Hospital pays non établi dans la noticeÉtablissement de santé
-
Policlinico San Matteo Fondazione pays non établi dans la noticeÉtablissement de santé
-
Azienda Ospedaliera Sant'Andrea pays non établi dans la noticeÉtablissement de santé
-
Ospedale Santa Maria pays non établi dans la noticeÉtablissement de santé
-
IRCCS “Regina Elena” National Cancer Institute Department of Urology pays non établi dans la noticeStructure de recherche
-
IRCCS "Regina Elena" National Cancer Institute Department of Urology pays non établi dans la noticeStructure de recherche
-
Fondazione Policlinico Universitario Campus Bio-Medico Department of Urology pays non établi dans la noticeÉtablissement de santé
-
San Camillo-Forlanini Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
IRCCS Fondazione Policlinico San Matteo Department of Oncology pays non établi dans la noticeÉtablissement de santé
-
Faculty of Health Sciences Department of Urology pays non établi dans la noticeUniversité ou école supérieure
Istituti di Ricovero e Cura a Carattere Scientifico, Campus Bio Medico University Hospital et Carlo Forlanini Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.